Key Takeaways Gilead will acquire Ouro Medicines for $1.675B upfront plus $500M in milestones, boosting its pipeline.GILD gains OM336, a bispecific T-cell engager showing early promise in autoimmune diseases like AIHA and ITP.GILD is exploring a partnership with Galapagos to co-develop OM336 and share development costs and royalties.Gilead Sciences (GILD) has agreed to acquire privately held biotechnology company Ouro Medicines, strengthening its push into innovative therapies for autoimmune diseases.The de ...

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]

Core Insights - The Zacks Equity Research team has highlighted several stocks, including Oracle Corp., T-Mobile US, Inc., Gilead Sciences, Inc., National Research Corp., and C&F Financial Corp., in their recent Analyst Blog [1][2] Oracle Corp. (ORCL) - Oracle's shares have outperformed the Zacks Computer - Software industry over the past year, with a growth of 11.6% compared to the industry's 2.7% [4] - The company reported strong fiscal Q3 2026 results, with earnings and revenues exceeding estimates, driven by an 84% surge in cloud infrastructure revenues due to AI workload and multicloud demand [4] - Free cash flow for the trailing 12 months was negative $13.2 billion as Oracle continues to invest aggressively in data center build-outs [5] - Competition from hyperscalers poses a risk to margins, and the transition from license revenue to subscription models may lead to near-term earnings volatility [6] T-Mobile US, Inc. (TMUS) - T-Mobile's shares have underperformed the Zacks Wireless National industry over the past six months, declining by 10.1% compared to the industry's 1.6% [7] - The company faces challenges due to macroeconomic factors, market saturation, and high debt burden, which could impact its premium valuation [7] - Despite these challenges, T-Mobile has achieved industry-leading postpaid customer growth and a record-low churn rate, bolstered by its acquisition strategy [8] - The company's 2.5 GHz 5G spectrum provides competitive advantages in speed and coverage [9] Gilead Sciences, Inc. (GILD) - Gilead's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months, with a growth of 30.6% compared to 19.5% for the industry [10] - The company reported better-than-expected fourth-quarter results, driven by its market-leading HIV franchise, particularly Biktarvy and Descovy [10] - Gilead expects HIV sales to grow approximately 6% in 2026, with Biktarvy projected to have a CAGR of around 6% over the next three years [11] - The company is also developing additional HIV treatments and strengthening its oncology and virology franchises through collaborations [12] National Research Corp. (NRC) - National Research's shares have outperformed the Zacks Business - Information Services industry over the past six months, with a growth of 0.5% compared to a decline of 15.2% for the industry [13] - The company's Total Recurring Contract Value (TRCV) has risen for five consecutive quarters, reaching approximately $152 million by March 2026 [13] - New sales increased by approximately 86% in 2025, indicating improved commercial execution [14] - However, the company has faced declining revenues for three consecutive years, which poses execution risks if TRCV does not translate into growth [15] C&F Financial Corp. (CFFI) - C&F Financial's shares have outperformed the Zacks Banks - Southeast industry over the past six months, with a growth of 1.5% compared to a decline of 5.3% for the industry [16] - The company benefits from a diversified three-segment model that supports stable earnings and reduces reliance on any single revenue stream [16] - Core banking expansion is driving recurring income, while mortgage banking performance is improving as originations recover [17] - Key risks include margin pressure from interest-rate shifts and rising operating expenses [18]

Summary of Gilead Sciences FY Conference Call (March 11, 2026) Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Key Focus**: Biopharmaceuticals, particularly in oncology and HIV treatment/prevention Core Points and Arguments Financial Performance - Gilead reported an extraordinary performance in 2025, with significant growth in earnings per share (EPS) and strong operating expense control [7] - The company is at the beginning of a long cycle with multiple product launches and the strongest pipeline in its history [7] Product Launches - **Yeztugo**: A once-every-six-month subcutaneous HIV prevention medicine, launched with extraordinary data showing 100% prevention in high-risk populations [23][24] - **Livdelzi**: A drug for liver disease (PBC) that has shown strong initial sales performance [7] - **Anito-cel**: Acquired through a deal with Arcellx for approximately $8 billion, this is a best-in-class BCMA cell therapy for multiple myeloma with a significant commercial opportunity estimated at over $20 billion [9][10] Market Opportunities - The multiple myeloma market is highlighted as a major opportunity, with Gilead's anito-cel showing a differentiated safety profile compared to competitors [11][14] - Gilead's oncology revenues reached approximately $3 billion, representing about 12% of total revenues, with expectations for steady growth in this segment [19][20] Yeztugo Launch Insights - The launch of Yeztugo is tracking well, with $150 million in sales reported for the first year and over 90% payer coverage achieved [24][26] - The company anticipates significant growth, projecting $800 million in sales for the upcoming year, driven by a growing patient base [22][28] Long-term Growth Strategy - Gilead aims to diversify its portfolio beyond HIV, with multiple upcoming product launches across various therapeutic areas, including oncology and liver disease [66][67] - The company has no major patent cliffs until 2036, allowing for sustained growth and investment in its pipeline [67] Challenges and Market Dynamics - The HIV treatment market is expected to shift towards long-acting therapies, with a significant portion of patients currently not diagnosed or not virally suppressed [42][43] - Despite some Medicaid coverage restrictions, Gilead does not foresee a material impact on its business from these changes [46][54] Community Engagement - Gilead is actively working to reach new populations affected by HIV, particularly in underserved communities, through targeted awareness campaigns [61] Additional Important Content - The company is experiencing a shift in the HIV prevention market, with a noted increase in patients starting on Yeztugo who are naive to HIV prevention therapies [25] - Gilead's commercial team is adapting strategies to raise awareness and reduce stigma associated with HIV treatment and prevention [61] - The overall HIV prevention market is expected to grow significantly, with a 50% increase reported from 2024 to 2025 [35][36] This summary encapsulates the key points discussed during the Gilead Sciences FY Conference Call, highlighting the company's financial performance, product launches, market opportunities, and strategic direction.

Core Viewpoint - The article discusses the potential resilience of CVS Health and Gilead Sciences during economic downturns, suggesting they are solid investments even in uncertain economic conditions [1]. Group 1: CVS Health - CVS Health operates over 9,000 locations in the U.S. and has established strong community relationships, which may help it navigate economic challenges [2]. - The company has faced challenges in its Medicare Advantage business but is focusing on profitable growth by scaling back this segment, which should improve margins and financial results [3]. - CVS Health offers an attractive dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, making it a solid choice for recession-resistant investment [3]. Group 2: Gilead Sciences - Gilead Sciences is a leading biotech company known for its strong portfolio in the HIV market, including key products like Biktarvy and Descovy, and has expanded into oncology and COVID-19 treatments [4]. - The company's HIV products are essential for patients, which should help maintain sales even during a recession, despite recent fluctuations in revenue from Veklury [5]. - Gilead has a robust pipeline in oncology that is expected to support future product launches and sales growth, positioning the company well for economic challenges [5].

Core Insights - Jefferies initiated coverage on Gilead Sciences with a Buy rating and a price target of $180, while assigning a Hold rating to Amgen with a target of $350, reflecting differing views on their respective valuations and growth potential [1][2] - JPMorgan maintained an Overweight rating on Oric Pharmaceuticals, emphasizing the unjustified nature of its recent stock pullback due to competitor news [1] Gilead Sciences (GILD) - Jefferies views Gilead as well-positioned due to a clean intellectual property runway until 2036, high operating margins, and the ability to invest in its pipeline while returning capital to shareholders [1] - Gilead reported Q4 2025 revenue of $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, up 2% year-over-year [1] - The company's flagship HIV therapy, Biktarvy, generated $3.97 billion in Q4, while Descovy surged 33% to $819 million [1] Amgen Inc. (AMGN) - Jefferies acknowledged Amgen's strong execution but concluded that a 35% stock run-up has left limited near-term upside, with the stock currently trading above the $350 target [1][2] - Amgen's Q4 revenue was $9.87 billion, surpassing the estimate of $9.66 billion, with a notable growth in Repatha at +44% to $870 million, while Enbrel saw a decline of 48% to $532 million [1] Oric Pharmaceuticals Inc. (ORIC) - JPMorgan's reaffirmation of Oric's Overweight rating comes after a 16.07% drop in shares due to competitor news, which the firm believes does not reflect the fundamentals of Oric's pipeline [1] - Oric's lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer, with a Phase 3 trial initiation expected in H1 2026 [1] - The company holds $392.3 million in cash, projecting a funding runway into the second half of 2028, with shares up 42.42% year-to-date despite recent pullbacks [1]

Core Insights - Jefferies has initiated coverage on Gilead Sciences with a Buy rating and a $180 price target, while assigning a Hold rating to Amgen with a $350 price target, indicating a nuanced view on the biopharma sector [3][5][10] Gilead Sciences - Gilead is positioned as one of the best large-cap biotechs, benefiting from a clean intellectual-property runway until 2036, high operating margins, and overlapping franchises [2][4] - Q4 2025 revenue was $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, reflecting a 2% year-over-year increase [7] - Non-GAAP EPS for Q4 was $1.86, slightly above the estimate of $1.85, and full-year non-GAAP EPS rose significantly to $8.15 from $4.62 in 2024 [7] - The HIV therapy Biktarvy generated $3.97 billion in Q4, up 5%, while Descovy surged 33% to $819 million, with the newly launched Yeztugo expected to be a commercial catalyst [7] - Gilead's stock is currently trading at $146.63, up 19.46% year-to-date, with a forward P/E of 16x reflecting guidance of non-GAAP EPS of $8.45 to $8.85 in 2026 [5][11] Amgen Inc. - Amgen reported Q4 revenue of $9.87 billion, surpassing the estimate of $9.66 billion, with non-GAAP EPS of $5.29, well above the $4.83 estimate [8] - The growth driver was Repatha, which increased by 44% to $870 million, while Enbrel saw a significant decline of 48% to $532 million [8] - Amgen shares are currently trading at $376.97, reflecting a 15.96% year-to-date increase, but are above Jefferies' $350 target, indicating limited near-term upside [5][12] Oric Pharmaceuticals - Oric is a clinical-stage oncology company with no product revenue, but its lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer [9] - The company holds $392.3 million in cash, providing a funding runway into the second half of 2028, despite a recent 16.07% drop in shares due to competitor news [6][9] - The consensus analyst target for Oric is $21.23, while its current price is $11.65, indicating potential upside [9] Analyst Perspectives - Gilead's long IP runway and diversified revenue base, along with a 2.2% dividend yield, make it attractive to income-oriented investors [13] - Amgen's stock has largely priced in strong execution, with risks from biosimilar competition and an unproven obesity pipeline [12][14] - Oric's binary risk nature is highlighted, with significant implications for stock performance based on upcoming clinical data readouts [15]

Gilead Sciences FY Conference Summary Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Event**: FY Conference held on March 03, 2026 Key Industry Insights 1. 2026 Guidance - Gilead provided a mid-single digit growth guidance of **4%-5%** for its base business in 2026, with an additional **2%** impact from ACA and MFN adjustments [13][14] - Specific guidance for the HIV segment indicates a **6%** year-over-year growth, primarily driven by the product **Biktarvy** [13][14] - The HIV prevention franchise, particularly **Descovy**, is expected to grow significantly, with guidance set at **$800 million**, up from **$150 million** in 2025 [14] 2. Product Performance - **Biktarvy** is recognized as the standard of care for HIV treatment, showing strong performance in both naive and switch patient populations [17][18] - The HIV prevention market is growing at approximately **55%**, with expectations for continued growth through 2026 [14][19] - **Yescarta**, an injectable product, is anticipated to see steady growth, supported by a **90%** access rate and a recent DTC campaign aimed at normalizing HIV prevention [21][25][26] 3. Market Dynamics - The overall HIV treatment market is projected to grow at **2-3%** annually, with **40%** of HIV-positive individuals in the U.S. not currently virologically suppressed [49][50] - Gilead is focusing on lifecycle management and patient-centric options to maintain its market leadership in HIV treatment [20][48] 4. Oncology Developments - Gilead announced the acquisition of **Arcellx**, which is expected to enhance its oncology portfolio, particularly in the multiple myeloma space, with a market potential of up to **$20 billion** [55][56] - The company is also preparing for a potential launch of **Trodelvy** in the first-line setting for breast cancer, following positive data from recent trials [60][61] 5. Inflammation Pipeline - Gilead's inflammation pipeline includes promising products in phase 2 trials, which are not yet fully recognized by investors [85][86] - The company aims to position its inflammation segment as a third pillar alongside its HIV and oncology businesses [85][86] Additional Considerations - Gilead is maintaining a disciplined approach to business development, with ongoing investments in early development deals while managing operational expenses [81][84] - The company is optimistic about its growth trajectory, particularly in the HIV prevention and treatment markets, and is focused on expanding its product offerings and market share [34][48][85]

Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to acquire Arcellx (ACLX) for $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion, enhancing Gilead's position in cell therapy [1][8] Acquisition Details - The acquisition focuses on anito-cel, a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma, which has demonstrated deep and durable responses with a manageable safety profile [4][11] - Gilead's subsidiary Kite Pharma already collaborates with Arcellx to co-develop anito-cel, indicating a strategic alignment between the two companies [2][11] - The deal includes a tender offer for all remaining Arcellx shares at a 68% premium to the 30-day volume-weighted average share price as of February 20, 2026 [9] Financial Implications - The acquisition is expected to be accretive to Gilead's earnings from 2028, strengthening its oncology and cell therapy portfolio [10][11] - Gilead currently holds approximately 11.5% of Arcellx's outstanding shares, which will be fully acquired through this transaction [9] Strategic Rationale - The acquisition allows Gilead to gain full control of anito-cel, streamlining development and commercialization processes, thereby enhancing long-term margin potential [11] - Gilead aims to diversify its revenue base and ramp up its oncology franchise, which has been under pressure [12] Market Context - Gilead anticipates ongoing competitive pressure in the cell therapies market, particularly from new entrants and established players like Bristol Myers (BMY), which has a strong cell-therapy portfolio [13] - The addition of anito-cel is expected to help Gilead offset declines in its existing cell therapy business [13]

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]